Literature DB >> 12045714

Length analysis of polymerase chain reaction products: a sensitive and reliable technique for the detection of mutations in KIT exon 11 in gastrointestinal stromal tumors.

Jean-François Emile1, Antoinette Lemoine, Nathalie Bienfait, Philippe Terrier, Daniel Azoulay, Brigitte Debuire.   

Abstract

Gastrointestinal stromal tumors are the most common mesenchymal neoplasms of the digestive tract. These tumors express the c-kit receptor tyrosine kinase, and many have activating mutations in the juxtamembrane region coded by the exon 11 of KIT. Detection of these mutations has prognostic and therapeutic impact. The aim of the study was to compare a new detection method by length analysis of polymerase chain reaction products (LAPP) to direct sequencing. The detection of either deletion or insertion mutations within the exon 11 of KIT was performed on genomic DNA extracted from 40 paraffin-embedded samples from 38 patients. Double-strand direct sequencing revealed a mutation in 25 of 40 samples. In two additional samples, a mutation was suspected but could not be determined by sequencing. LAPP revealed a mutation in 27 samples, corresponding to the 25 determined and 2 suspected samples. One of these latter samples contained three different alleles. Mutations corresponded to either deletions (n = 24) or insertion (n = 1) and had the same size with sequencing and LAPP. Our results show that LAPP is as accurate and more sensitive than direct sequencing for the detection of deletion or insertion mutations of exon 11 of KIT in gastrointestinal stromal tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12045714     DOI: 10.1097/00019606-200206000-00007

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  11 in total

1.  Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs.

Authors:  J F Emile; S Brahimi; J M Coindre; P P Bringuier; G Monges; P Samb; L Doucet; I Hostein; B Landi; M P Buisine; A Neuville; O Bouché; P Cervera; J L Pretet; J Tisserand; A Gauthier; A Le Cesne; J C Sabourin; J Y Scoazec; S Bonvalot; C L Corless; M C Heinrich; J Y Blay; P Aegerter
Journal:  Med Oncol       Date:  2011-09-28       Impact factor: 3.064

Review 2.  Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.

Authors:  Simon B Zeichner; Daniel A Goldstein; Christine Kohn; Christopher R Flowers
Journal:  J Gastrointest Oncol       Date:  2017-06

3.  Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.

Authors:  Qiulu Pan; William Pao; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

4.  Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.

Authors:  Nicolas F Delahaye; Sylvie Rusakiewicz; Isabelle Martins; Cédric Ménard; Stephan Roux; Luc Lyonnet; Pascale Paul; Matthieu Sarabi; Nathalie Chaput; Michaela Semeraro; Véronique Minard-Colin; Vichnou Poirier-Colame; Kariman Chaba; Caroline Flament; Véronique Baud; Hélène Authier; Saadia Kerdine-Römer; Marc Pallardy; Isabelle Cremer; Laetitia Peaudecerf; Bénédita Rocha; Dominique Valteau-Couanet; Javier Celis Gutierrez; Jacques A Nunès; Frédéric Commo; Sylvie Bonvalot; Nicolas Ibrahim; Philippe Terrier; Paule Opolon; Cristina Bottino; Alessandro Moretta; Jan Tavernier; Pascal Rihet; Jean-Michel Coindre; Jean-Yves Blay; Nicolas Isambert; Jean-François Emile; Eric Vivier; Axel Lecesne; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2011-05-08       Impact factor: 53.440

5.  KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors.

Authors:  Christopher L Corless; Laura McGreevey; Ajia Town; Arin Schroeder; Troy Bainbridge; Patina Harrell; Jonathan A Fletcher; Michael C Heinrich
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

6.  Microfluidic deletion/insertion analysis for rapid screening of KIT and PDGFRA mutations in CD117-positive gastrointestinal stromal tumors: diagnostic applications and report of a new KIT mutation.

Authors:  Alberto Zamò; Anna Bertolaso; Ilaria Franceschetti; Gregor Weirich; Paola Capelli; Sara Pecori; Marco Chilosi; Heinz Hoefler; Fabio Menestrina; Aldo Scarpa
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

7.  Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism.

Authors:  N Théou-Anton; S Tabone; D Brouty-Boyé; R Saffroy; L Ronnstrand; A Lemoine; J-F Emile
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

8.  Prognosis and predictive value of KIT exon 11 deletion in GISTs.

Authors:  J-B Bachet; I Hostein; A Le Cesne; S Brahimi; A Beauchet; S Tabone-Eglinger; F Subra; B Bui; F Duffaud; P Terrier; J-M Coindre; J-Y Blay; J-F Emile
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

9.  Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors.

Authors:  Jean-Baptiste Bachet; Jean-François Emile
Journal:  Appl Clin Genet       Date:  2010-10-29

10.  Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples.

Authors:  Jean-Baptiste Bachet; Séverine Tabone-Eglinger; Sophie Dessaux; Anthony Besse; Sabrina Brahimi-Adouane; Jean-François Emile; Jean-Yves Blay; Laurent Alberti
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.